 "Glenmark, Roche agree to end patent litigation for cancer drug Tarceva")
Glenmark Pharmaceuticals has agreed to an out of court settlement with Roche for a patent litigation over Roche’s lung cancer drug erlotinib hydrochloride sold under the brand name Tarceva, according to a PTI report.
“Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - erlotinib hydrochloride. As part of the agreement, the companies have ceased all relevant patent litigation on this product and Glenmark has acknowledged the patent rights of Roche,” said the Mumbai-based pharma major in a BSE filing on January 5, 2016.
Tarceva is developed and commercialised by Astellas Pharma US in partnership with Genentech in the US, Chugai in Japan and Roche in the rest of the world.
Roche, which was granted the patent for erlotinib hydrochloride in India in February 2007, was involved in patent disputes with Cipla over Tarceva. It was only in November 2015 that Delhi High Court pronounced a judgement in favour of Roche and ruled that Cipla’s generic version of the drug infringed Swiss drug maker’s Tarceva patent.
“Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - erlotinib hydrochloride. As part of the agreement, the companies have ceased all relevant patent litigation on this product and Glenmark has acknowledged the patent rights of Roche,” said the Mumbai-based pharma major in a BSE filing on January 5, 2016.
Tarceva is developed and commercialised by Astellas Pharma US in partnership with Genentech in the US, Chugai in Japan and Roche in the rest of the world.
Roche, which was granted the patent for erlotinib hydrochloride in India in February 2007, was involved in patent disputes with Cipla over Tarceva. It was only in November 2015 that Delhi High Court pronounced a judgement in favour of Roche and ruled that Cipla’s generic version of the drug infringed Swiss drug maker’s Tarceva patent.